![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Adamis Pharmaceuticals’ EpiPen Competitor
FDA Approves Adamis Pharmaceuticals’ EpiPen Competitor
June 21, 2017
Amid a firestorm of controversy surrounding Mylan’s EpiPen, the FDA has approved an alternative.
San Diego-based Adamis Pharmaceuticals announced the FDA approved Sympeji, its single-dose epinephrine injectable candidate for severe allergic reactions.
Mylan’s response to potential competitors has been a source of controversy. In April, Sanofi sued the drugmaker, alleging its anticompetitive practices kept the Auvi-Q, Sanofi’s competitor, from gaining traction within the market, costing it millions in lost sales while the EpiPen maintained 90 percent command of the auto-injector market. — Zack Budryk
Upcoming Events
-
21Oct